Advances in the treatment of moderate-to-severe plaque psoriasis-Reference-Cited by-同舟云学术

Advances in the treatment of moderate-to-severe plaque psoriasis

Published:2011-05-01 Issue:9 Volume:68 Page:795-806
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Herrier Richard N.¹

Affiliation:

1. College of Pharmacy, University of Arizona, Drachman Building, Room 211J, 1295 North Martin, P.O. Box 210202, Tucson, AZ 85721-0202

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/68/9/795/28349321/ajhp0795.pdf

Reference106 articles.

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Psoriasis. www.niams.nih.gov/Health_Info/Psoriasis/default.asp (accessed 2011 Jan 14).

2. Biologics in psoriasis: a quick reference guide;Thomas;J Am Acad Dermatol.,2005

3. Pathogenesis and clinical features of psoriasis;Griffiths;Lancet.,2007

4. Management of moderate to severe plaque psoriasis (part 1): clinical update on antitumor necrosis factor agents;Sobell;J Drugs Dermatol.,2009

5. Psoriasis;Nestle;N Engl J Med.,2009

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02;Immunotherapy Advances;2023-12-21

2. Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study;BioDrugs;2023-05-19

3. Infliximab, Golimumab, and Certolizumab Pegol;Advances in Psoriasis;2020-11-27

4. Telemedicine approach for psoriasis management, time for application? A systematic review of published studies;Dermatologic Therapy;2020-07-13

5. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients;Journal of Dermatological Treatment;2017-01-18